Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375452 | 1.00 | AHR (0.50) | AHRKDM4EHTTUSP2GAA | |
| SCHEMBL12701071 | 0.86 | NR4A1 (0.50) | KDM4EHTTUSP2GAAMEN1 | |
| SCHEMBL14898537 | 0.84 | P2RX7 (0.48) | AHRKDM4EHTTUSP2GAA | |
| SCHEMBL28227760 | 0.83 | ALDH1A1 (0.46) | KDM4EHTTUSP2GAAMEN1 | |
| SCHEMBL17433767 | 0.83 | BACE1 (0.51) | GAAKMT2AMAPTPOLBTP53 | |
| SCHEMBL29364387 | 0.82 | KDM4E (0.68) | KDM4EHTTUSP2GAAMEN1 | |
| SCHEMBL10263150 | 0.82 | KDM4E (0.68) | KDM4EHTTUSP2GAAMEN1 | |
| SCHEMBL17433840 | 0.82 | MEN1 (0.46) | KDM4EHTTUSP2GAAMEN1 | |
| SCHEMBL14113741 | 0.81 | ALDH1A1 (0.50) | KDM4EMEN1KMT2ACYP1A2MAPT | |
| SCHEMBL13209738 | 0.79 | KDM4E (0.69) | AHRKDM4EHTTUSP2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708568-B1 | COMPOUND CAPABLE OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD, AND MEDICAL USE THEREOF | HEFEI INDUSTRIAL PHARMACEUTICAL INST CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-11161860-B2 | Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof | Hefei Industrial Pharmaceutical Institute Co., Ltd (CN) | 2021-11-02 | — | — | US | disclosed |
| US-20210179640-A1 | COMPOUND HAVING EFFECTS OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | HEFEI INDUSTRIAL PHARMACEUTICAL INSTITUTE CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3708568-A1 | COMPOUND CAPABLE OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD, AND MEDICAL USE THEREOF | Hefei Industrial Pharmaceutical Institute Co., Ltd (CN) | 2020-09-16 | — | — | EP | disclosed |
| CN-108148085-B | With compound, preparation method and its medicinal usage for inhibiting phosphodiesterase 4 | Hefei Medical and Pharmaceutical Co., Ltd. (CN) | 2019-11-01 | — | — | CN | disclosed |
| CN-108148085-A | With compound, preparation method and its medicinal usage for inhibiting phosphodiesterase 4 | 合肥医工医药有限公司 | 2018-06-12 | — | — | CN | disclosed |
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-9150568-B2 | Compositions and methods for modulating FXR | NOVARTIS AG (CH) | 2015-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366856-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | AHR 867/4885KDM4E 3613/4885HTT 4690/4885 |
| US-20210179640-A1 | COMPOUND HAVING EFFECTS OF INHIBITING PHOSPHODIESTERASE 4, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | PDE4A, PDE3B, PDE4B | AHR 2893/4885KDM4E 652/4885HTT 4596/4885 |
| US-11161860-B2 | Compound having effects of inhibiting phosphodiesterase 4, preparation method thereof and pharmaceutical use thereof | PDE4A, PDE3B, PDE4B | AHR 2893/4885KDM4E 652/4885HTT 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.